

# Michael Oellerich

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/6824109/michael-oellerich-publications-by-citations.pdf>

**Version:** 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

41  
papers

1,909  
citations

20  
h-index

43  
g-index

43  
ext. papers

2,317  
ext. citations

4.6  
avg, IF

4.42  
L-index

#	Paper	IF	Citations
41	Opportunities to optimize tacrolimus therapy in solid organ transplantation: report of the European consensus conference. <i>Therapeutic Drug Monitoring</i> , <b>2009</b> , 31, 139-52	3.2	347
40	The pharmacokinetic-pharmacodynamic relationship for total and free mycophenolic Acid in pediatric renal transplant recipients: a report of the german study group on mycophenolate mofetil therapy. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2002</b> , 13, 759-768	12.7	192
39	Rapid Liquid Chromatography-Tandem Mass Spectrometry Routine Method for Simultaneous Determination of Sirolimus, Everolimus, Tacrolimus, and Cyclosporin A in Whole Blood. <i>Clinical Chemistry</i> , <b>2002</b> , 48, 955-958	5.5	177
38	Digital droplet PCR for rapid quantification of donor DNA in the circulation of transplant recipients as a potential universal biomarker of graft injury. <i>Clinical Chemistry</i> , <b>2013</b> , 59, 1732-41	5.5	169
37	Proteome of conidial surface associated proteins of <i>Aspergillus fumigatus</i> reflecting potential vaccine candidates and allergens. <i>Journal of Proteome Research</i> , <b>2006</b> , 5, 954-62	5.6	97
36	Graft-derived cell-free DNA, a noninvasive early rejection and graft damage marker in liver transplantation: A prospective, observational, multicenter cohort study. <i>PLoS Medicine</i> , <b>2017</b> , 14, e1002286	11.6	95
35	Using circulating cell-free DNA to monitor personalized cancer therapy. <i>Critical Reviews in Clinical Laboratory Sciences</i> , <b>2017</b> , 54, 205-218	9.4	77
34	Two-hour cyclosporine concentration determination: an appropriate tool to monitor neoral therapy?. <i>Therapeutic Drug Monitoring</i> , <b>2002</b> , 24, 40-6	3.2	73
33	Therapeutic Drug Monitoring of Everolimus: A Consensus Report. <i>Therapeutic Drug Monitoring</i> , <b>2016</b> , 38, 143-69	3.2	71
32	Absolute quantification of donor-derived cell-free DNA as a marker of rejection and graft injury in kidney transplantation: Results from a prospective observational study. <i>American Journal of Transplantation</i> , <b>2019</b> , 19, 3087-3099	8.7	65
31	Barcelona Consensus on Biomarker-Based Immunosuppressive Drugs Management in Solid Organ Transplantation. <i>Therapeutic Drug Monitoring</i> , <b>2016</b> , 38 Suppl 1, S1-20	3.2	57
30	Liquid chromatography-tandem mass spectrometry or automated immunoassays: what are the future trends in therapeutic drug monitoring?. <i>Clinical Chemistry</i> , <b>2012</b> , 58, 821-5	5.5	48
29	Biomarkers as a tool for management of immunosuppression in transplant patients. <i>Therapeutic Drug Monitoring</i> , <b>2010</b> , 32, 560-72	3.2	46
28	Leveraging the real value of laboratory medicine with the value proposition. <i>Clinica Chimica Acta</i> , <b>2016</b> , 462, 183-186	6.2	44
27	Use of graft-derived cell-free DNA as an organ integrity biomarker to reexamine effective tacrolimus trough concentrations after liver transplantation. <i>Therapeutic Drug Monitoring</i> , <b>2014</b> , 36, 136-40	3.2	39
26	Graft-derived cell-free DNA as an early organ integrity biomarker after transplantation of a marginal HELLP syndrome donor liver. <i>Transplantation</i> , <b>2014</b> , 98, e43-5	1.8	29
25	Biomarkers: the link between therapeutic drug monitoring and pharmacodynamics. <i>Therapeutic Drug Monitoring</i> , <b>2006</b> , 28, 35-8	3.2	28

24	Synergistic effects of sirolimus with cyclosporine and tacrolimus: analysis of immunosuppression on lymphocyte proliferation and activation in rat whole blood. <i>Transplantation</i> , <b>2004</b> , 77, 1154-62	1.8	25
23	Diagnostic value of alpha-1-fetoprotein (AFP) as a biomarker for hepatocellular carcinoma recurrence after liver transplantation. <i>Clinical Biochemistry</i> , <b>2018</b> , 52, 20-25	3.5	22
22	Circulating Cell-Free DNA-Diagnostic and Prognostic Applications in Personalized Cancer Therapy. <i>Therapeutic Drug Monitoring</i> , <b>2019</b> , 41, 115-120	3.2	20
21	Cell-Free Plasma DNA for Disease Stratification and Prognosis in Head and Neck Cancer. <i>Clinical Chemistry</i> , <b>2018</b> , 64, 959-970	5.5	18
20	Immunosuppressive drug monitoring of sirolimus and cyclosporine in pediatric patients. <i>Clinical Biochemistry</i> , <b>2004</b> , 37, 424-8	3.5	18
19	Mycophenolic acid interaction with cyclosporine and tacrolimus in vitro and in vivo: evaluation of additive effects on rat blood lymphocyte function. <i>Therapeutic Drug Monitoring</i> , <b>2005</b> , 27, 123-31	3.2	18
18	Personalized Therapy for Mycophenolate: Consensus Report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. <i>Therapeutic Drug Monitoring</i> , <b>2021</b> , 43, 150-200	3.2	17
17	Plasma EGFR mutation testing in non-small cell lung cancer: A value proposition. <i>Clinica Chimica Acta</i> , <b>2019</b> , 495, 481-486	6.2	15
16	Time-Dependent Apparent Increase in dd-cfDNA Percentage in Clinically Stable Patients Between One and Five Years Following Kidney Transplantation. <i>Clinical Chemistry</i> , <b>2020</b> , 66, 1290-1299	5.5	13
15	Liquid biopsies: donor-derived cell-free DNA for the detection of kidney allograft injury. <i>Nature Reviews Nephrology</i> , <b>2021</b> , 17, 591-603	14.9	12
14	Fetal calf serum heat inactivation and lipopolysaccharide contamination influence the human T lymphoblast proteome and phosphoproteome. <i>Proteome Science</i> , <b>2011</b> , 9, 71	2.6	10
13	Therapeutic drug monitoring - Key to personalized pharmacotherapy. <i>Clinical Biochemistry</i> , <b>2017</b> , 50, 375-379	3.5	9
12	A value proposition for natriuretic peptide measurement in the assessment of patients with suspected acute heart failure. <i>Clinica Chimica Acta</i> , <b>2020</b> , 500, 98-103	6.2	9
11	Thiopurines induce oxidative stress in T-lymphocytes: a proteomic approach. <i>Mediators of Inflammation</i> , <b>2015</b> , 2015, 434825	4.3	7
10	Identification of the novel interacting partners of the mammalian target of rapamycin complex 1 in human CCRF-CEM and HEK293 cells. <i>International Journal of Molecular Sciences</i> , <b>2014</b> , 15, 4823-36	6.3	7
9	Donor-Derived Cell-Free DNA Testing in Solid Organ Transplantation: A Value Proposition. <i>Journal of applied laboratory medicine</i> , <b>2020</b> , 5, 993-1004	2	7
8	A Universal Droplet Digital PCR Approach for Monitoring of Graft Health After Transplantation Using a Preselected SNP Set. <i>Methods in Molecular Biology</i> , <b>2018</b> , 1768, 335-348	1.4	5
7	Crosstalk between Edc4 and mammalian target of rapamycin complex 1 (mTORC1) signaling in mRNA decapping. <i>International Journal of Molecular Sciences</i> , <b>2014</b> , 15, 23179-95	6.3	5

6	Graft-Derived Cell-Free DNA as a Noninvasive Biomarker of Cardiac Allograft Rejection: a Cohort Study on Clinical Validity and Confounding Factors. <i>Transplantation</i> , <b>2021</b> ,	1.8	4
5	Temporary antimetabolite treatment hold boosts SARS-CoV-2 vaccination-specific humoral and cellular immunity in kidney transplant recipients.. <i>JCI Insight</i> , <b>2022</b> ,	9.9	4
4	Establishment of thiopurine S-methyltransferase gene knockdown in jurkat T-lymphocytes: an in vitro model of TPMT polymorphism. <i>Therapeutic Drug Monitoring</i> , <b>2012</b> , 34, 584-92	3.2	3
3	Absolute or Relative Quantification of Donor-derived Cell-free DNA in Kidney Transplant Recipients: Case Series. <i>Transplantation Direct</i> , <b>2021</b> , 7, e778	2.3	3
2	Temporary hold of mycophenolate boosts SARS-CoV-2 vaccination-specific humoral and cellular immunity in kidney transplant recipients		2
1	Implementation of medical tests in a Value-Based healthcare environment: A framework for delivering value. <i>Clinica Chimica Acta</i> , <b>2021</b> , 521, 90-96	6.2	1